Basal and pentagastrin-stimulated calcitonin cut-off values in diagnosis of preoperative medullary thyroid cancer

Background/aim: Medullary thyroid cancer (MTC) originates from parafollicular cells (C cell) and produces calcitonin (CT). Basal serum CT was used in the diagnosis and treatment of MTC. If basal CT level is 100 pg/mL or higher, it is likely to have MTC, but if basal CT level is below 10 pg/mL, the probability of developing thyroid disease is low. In cases with basal CT level between 10–100 pg/mL, pentagastrin-stimulated (PS) CT level is studied to evaluate MTC and C cell hyperplasia (CHH). This study aimed to determine cut-off value for basal and PS peak CT level for diagnosis of MTC. Materials and methods: We retrospectively reviewed files of patients presented to endocrine outpatient clinic of Ege University, Medicine School, between 2010 and 2019; 176 patients with basal CT level of 10–100 pg/mL and patients with PS test were included to the study. Results: The receiver operating characteristic curve (ROC) analysis was used to determine cut-off value for basal CT that can discriminate cases with MTC and those with nodular goiter. Cut-off value for basal CT was calculated as 46.5 pg/mL (specificity; 100 %, sensitivity; 74 %). In the ROC analysis for peak PS CT, cut-off value was calculated as 285 pg/mL (specificity:100 %; sensitivity:82 %). When peak CT level was > 290 pg/mL in PS test, both specificity and sensitivity for MTC were determined as 100 %. The PS peak CT level > 285 pg/ mL was significant for MTC diagnosis while range of 117–274 pg/mL was significant for CHH. Conclusion: In this study, cut-off value was calculated as 46.5 pg/mL for basal CT, whereas 285 pg/mL for PS peak CT in the diagnosis of preoperative MTC.Key words: Medullary thyroid cancer, C cell hyperplasia, calcitonin, pentagastrin, cut-of

PDF

___

1. Cohen R, Campos J-M, Salaün C, Massoud Heshmati H, Kraimps J-L et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism 2000; 85 (2): 919-919. doi:10.1210/jcem.85.2.6556
2. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proceedings of the National Academy of Sciences of the United States of America 1994; 91 (4): 1579- 1583. doi:10.1073/pnas.91.4.1579
3. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Human Molecular Genetics 1993; 2 (7): 851-856. doi:10.1093/hmg/2.7.851
4. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: Results in 899 patients. Clinical Endocrinology 1998; 48 (3): 265-273. doi:10.1046/ j.1365-2265.1998.00392.x
5. Costante G, Meringolo D, Durante C, Bianchi D, Nocera M et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. Journal of Clinical Endocrinology and Metabolism. 2007; 92 (2): 450-455. doi:10.1210/jc.2006-1590
6. Pina G, Dubois S, Murat A, Berger N, Niccoli P et al. Is basal ultrasensitive measurement of calcitonin capable of substituting for the pentagastrin-stimulation test? Clinical Endocrinology. 2013;78 (3): 358-364. doi:10.1111/cen.12001
7. Toledo SPA, Lourenço DM, Santos MA, Tavares MR, Toledo RA et al. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics. 2009; 64 (7): 699-706. doi:10.1590/S1807-59322009000700015
8. Guyétant S, Rousselet M-C, Durigon M, Chappard D, Franc B et al. Sex-Related C Cell Hyperplasia in the Normal Human Thyroid: A Quantitative Autopsy Study. The Journal of Clinical Endocrinology & Metabolism. 1997; 82 (1): 42-47. doi:10.1210/ jcem.82.1.3684
9. Hazard JB, Hawk WA, Crile G. Medullary (solıd) carcınoma of the thyroıd—a clınıcopathologıc entıty. Journal of Clinical Endocrinology and Metabolism 1959;19 (1): 152-161. doi:10.1210/jcem-19-1-152
10. Melvin KE, Tashjian AH. The syndrome of excessive thyrocalcitonin produced by medullary carcinoma of the thyroid. Proceedings of the National Academy of Sciences of the United States of America 1968; 59 (4): 1216-1222. doi:10.1073/pnas.59.4.1216
11. Bergholm U, Adami HO, Telenius-Berg M, Johansson H, Wilander E. Incidence of sporadic and familial medullary thyroid carcinoma in Sweden 1959 through 1981: A nationwide study in 126 patients. Acta Oncologica 1990; 29 (1): 9-15. doi:10.3109/02841869009089985
12. Keiser HR, Beaven MA, Doppman J, Wells S, Buja LM. Sipple’s syndrome: medullary thyroid carcinoma, pheochromocytoma, and parathyroid disease. Studies in a large family. NIH conference. Annals of internal medicine 1973; 78 (4): 561-579. doi:10.7326/0003-4819-78-4-561
13. GHARIB H, Mcconahey WM, Tiegs RD, Bergstralh EJ, Goellner JR et al. Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clinic Proceedings 1992; 67 (10): 934-940. doi:10.1016/S0025-6196(12)60923-9
14. E K, PH I, AE S, QY D, OH C. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000; 88 (5). doi:10.1002/(SICI)1097-0142(20000301)88:5<1139::AIDCNCR26>3.0.CO;2-Z
15. Özgen AG, Hamulu F, Bayraktar F, Yilmaz C, Tüzün M et al. Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. Thyroid. 1999; 9 (6): 579-582. doi:10.1089/thy.1999.9.579
16. Pacini F, Fontanelli M, Fugazzola L, Elisei R, Romei C et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism 1994; 78 (4): 826-829. doi:10.1210/jcem.78.4.8157706
17. Niccoli P, Wion-Barbot N, Caron P, Henry JF, De Micco C et al. Interest of routine measurement of serum calcitonin: Study in a large series of thyroidectomized patients. Journal of Clinical Endocrinology and Metabolism 1997; 82 (2): 338-341. doi:10.1210/jcem.82.2.3737
18. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. Journal of Clinical Endocrinology and Metabolism 2004; 89 (1):163-168. doi:10.1210/jc.2003-030550
19. Vierhapper H, Raber W, Bieglmayer C, Kaserer K, Weinhäusl A et al. Routine measurement of plasma calcitonin in nodular thyroid diseases. Journal of Clinical Endocrinology and Metabolism 1997; 82 (5):1589-1593. doi:10.1210/ jcem.82.5.3949
20. Borchhardt KA, Hörl WH, Sunder-Plassmann G. Reversibility of “secondary hypercalcitoninemia” after kidney transplantation. American Journal of Transplantation. 2005; 5 (7): 1757-1763. doi:10.1111/j.1600-6143.2005.00908.x
21. Bevilacqua M, Dominguez LJ, Righini V, Valdes V, Vago T et al. Dissimilar PTH, gastrin, and calcitonin responses to oral calcium and peptones in hypocalciuric hypercalcemia, primary hyperparathyroidism, and normal subjects: A useful tool for differential diagnosis. Journal of Bone and Mineral Research 2006; 21 (3): 406-412. doi:10.1359/JBMR.051210
22. Schuetz M, Duan H, Wahl K, Pirich C, Antoni A et al. T lymphocyte cytokine production patterns in hashimoto patients with elevated calcitonin levels and their relationship to tumor initiation. Anticancer Research 2006; 26 (6B): 4591- 4596.
23. Pratz KW, Ma C, Aubry M-C, Vrtiska TJ, Erlichman C. Large cell carcinoma with calcitonin and vasoactive ıntestinal polypeptide–associated verner-morrison syndrome. Mayo Clinic Proceedings 2005; 80 (1): 116-120. doi:10.1016/S0025- 6196(11)62968-6
24. Shi X, Liu R, Basolo F, Giannini R, Shen X et al. Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. The Journal of Clinical Endocrinology & Metabolism 2016; 101 (1): 264-274. doi:10.1210/jc.2015- 2917
25. Machens A, Haedecke J, Holzhausen HJ, Thomusch O, Schneyer U et al. Differential diagnosis of calcitonin-secreting neuroendocrine carcinoma of the foregut by pentagastrin stimulation. Langenbeck’s Archives of Surgery 2000; 385 (6): 398-401. doi:10.1007/s004230000169
26. Erdogan MF, Gursoy A, Kulaksizoglu M. Long-term effects of elevated gastrin levels on calcitonin secretion. Journal of Endocrinological Investigation. 2006; 29 (9): 771-775. doi:10.1007/BF03347369
27. Perros P, Boelaert K, Colley S, Evans C, Evans RM et al. Guidelines for the management of thyroid cancer. Clinical Endocrinology 2014; 81(SUPPL. 1):1-122. doi:10.1111/ cen.12515
28. d’Herbomez M, Caron P, Bauters C, Cao C Do, Schlienger JL et al. Reference range of serum calcitonin levels in humans: Influence of calcitonin assays, sex, age, and cigarette smoking. European Journal of Endocrinology 2007; 157 (6): 749-755. doi:10.1530/EJE-07-0566
29. Guyétant S, Rousselet M-C, Durigon M, Chappard D, Franc B et al. Sex-Related C Cell Hyperplasia in the Normal Human Thyroid: A Quantitative Autopsy Study. The Journal of Clinical Endocrinology & Metabolism 1997; 82 (1): 42-47. doi:10.1210/ jcem.82.1.3684
30. Basuyau JP, Mallet E, Leroy M, Brunelle P. Reference intervals for serum calcitonin in men, women, and children. Clinical Chemistry 2004; 50 (10):1828-1830. doi:10.1373/ clinchem.2003.026963
31. Kratzsch J, Petzold A, Raue F, Reinhardt W, Bröcker-Preuß M et al. Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer. Clinical Chemistry. 2011; 57 (3): 467-474. doi:10.1373/ clinchem.2010.151688
32. Colombo C, Verga U, Mian C, Ferrero S, Perrino M et al. Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2012; 97 (3): 905-913. doi:10.1210/jc.2011-2033
33. Doyle P, Düren C, Nerlich K, Verburg FA, Grelle I et al. Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adults. Journal of Clinical Endocrinology and Metabolism 2009; 94 (8): 2970-2974. doi:10.1210/jc.2008-2403
34. Russo M, Scollo C, Padova G, Vigneri R, Pellegriti G. Cardiac arrest after intravenous calcium administration for calcitonin stimulation test. Thyroid 2014; 24 (3): 606-607. doi:10.1089/ thy.2013.0394
35. Mian C, Perrino M, Colombo C, Cavedon E, Pennelli G et al. Refining calcium test for the diagnosis of medullary thyroid cancer: Cutoffs, procedures, and safety. Journal of Clinical Endocrinology and Metabolism 2014; 99 (5): 1656-1664. doi:10.1210/jc.2013-4088
36. Niederle MB, Scheuba C, Gessl A, Li S, Koperek O et al. Calcium-stimulated calcitonin - The “new standard” in the diagnosis of thyroid C-cell disease-clinically relevant genderspecific cut-off levels for an “old test.” Biochemia Medica 2018; 28 (3). doi:10.11613/BM.2018.030710
37. Rink T, Truong PN, Schroth HJ, Diener J, Zimny M et al. Calculation and validation of a plasma calcitonin limit for early detection of medullary thyroid carcinoma in nodular thyroid disease. Thyroid. 2009; 19 (4): 327-332. doi:10.1089/ thy.2008.0102
38. Niccoli P, Wion-Barbot N, Caron P, Henry JF, De Micco C et al. Interest of routine measurement of serum calcitonin: Study in a large series of thyroidectomized patients. Journal of Clinical Endocrinology and Metabolism 1997; 82 (2): 338-341. doi:10.1210/jcem.82.2.3737
39. Elisei R. Routine serum calcitonin measurement in the evaluation of thyroid nodules. Best Practice and Research: Clinical Endocrinology and Metabolism 2008; 22 (6): 941-953. doi:10.1016/j.beem.2008.09.008
40. Hodak SP, Burman KD. Editorial: The Calcitonin Conundrum - Is It time for routine measurement of serum calcitonin in patients with thyroid nodules? Journal of Clinical Endocrinology and Metabolism. 2004; 89 (2): 511-514. doi:10.1210/jc.2003-031983
41. Dietlein M, Wieler H, Schmidt M, Schwab R, Goretzki PE et al. [Routine measurement of serum calcitonin in patients with nodular thyroid disorders?]. Nuklearmedizin Nuclear medicine 2008; 47 (2): 65-72. doi:10.3413/nukmed-0125
42. Scheuba C, Kaserer K, Weinhäusl A, Pandev R, Kaider A et al. Is medullary thyroid cancer predictable? A prospective study of 86 patients with abnormal pentagastrin tests. Surgery 1999; 126 (6): 1089-1096. doi:10.1067/msy.2099.102268
43. Milone F, Ramundo V, Chiofalo MG, Severino R, Paciolla I et al. Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels. Clinical Endocrinology 2010; 73 (1): 85-88. doi:10.1111/j.1365-2265.2009.03759.x
44. Karges W, Dralle H, Raue F, Mann K, Reiners C et al. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: german evidence-based consensus recommendation. Experimental and Clinical Endocrinology and Diabetes 2004; 112 (1): 52-58. doi:10.1055/s-2004-815727a